Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

‘Robustly’ inhibiting glucocorticoid pathway
February 2020
SHARING OPTIONS:

SOUTH SAN FRANCISCO, Calif.—ORIC Pharmaceuticals recently presented new preclinical data on ORIC-101, a glucocorticoid receptor (GR) antagonist currently in a Phase 1b clinical trial in combination with nab-paclitaxel in patients with advanced solid tumors. The presentation was at the 2019 San Antonio Breast Cancer Symposium involving a poster titled “ORIC-101 Robustly Inhibits the Glucocorticoid Pathway and Overcomes Chemoresistance in TNBC.”  GR is highly expressed in such cancers as prostate, pancreatic, ovarian, triple-negative breast and endometrial. Studies have indicated that activation of GR reduces the efficacy of chemotherapy, while inhibition of GR with the antagonist ORIC-101 enhances the efficacy of chemotherapy in multiple solid tumor models.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.